Citizens Financial Group Inc. RI Increases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Citizens Financial Group Inc. RI increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,301 shares of the company’s stock after purchasing an additional 263 shares during the period. Citizens Financial Group Inc. RI’s holdings in Novo Nordisk A/S were worth $1,703,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC increased its holdings in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S during the second quarter valued at approximately $25,000. Halpern Financial Inc. boosted its stake in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Finally, Abound Wealth Management boosted its stake in shares of Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after acquiring an additional 157 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 2.4 %

NVO opened at $105.07 on Friday. The stock has a 50-day moving average of $115.48 and a 200 day moving average of $128.79. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The firm has a market cap of $471.50 billion, a P/E ratio of 34.00, a P/E/G ratio of 1.32 and a beta of 0.42.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.